Assessing the role of ADAM10 in Trastuzumab treatment and resistance
<p>Overexpression of the HER2 receptor occurs in about 15-20% of all breast cancers and is correlated with poor prognosis. Trastuzumab (Herceptin®), a monoclonal antibody targeting HER2, was shown to prolong survival of these patients. However, primary or acquired resistance remains a drawback...
| Հիմնական հեղինակ: | |
|---|---|
| Այլ հեղինակներ: | |
| Ձևաչափ: | Թեզիս |
| Լեզու: | English |
| Հրապարակվել է: |
2012
|
| Խորագրեր: |